27 April 2011 Business
Industry news, May 2011
Japanese firm Otsuka has agreed to buy the Anglo-American Astex Pharmaceuticals for $886 million (£569 million) in cash. The deal gives Otsuka access to revenues from Astex’s blood cancer drug Dacogen (decitabine), as well as other candidates in clinical development.
It also includes Astex’s fragment-based drug discovery arm, based in Cambridge, UK. While the company’s innovative approach has yet to produce a molecule that has made it all the way to market (Dacogen came from Astex’s merger with SuperGen in 2011), Otsuka’s leaders clearly have faith in its potential. ‘I would like Otsuka Pharmaceutical to continue to respect Astex's uniqueness and leverage it to bring further growth for Otsuka,’ company president Taro Iwamoto said in a statement.
3 December 2013 Research
Innovative electrodes set to put electric cars in the fast lane with a new design that holds double the energy of ordinary li...
21 November 2013 Comments
Once appalled by the military use of his discoveries, Frederick Soddy would pleased by his legacy today, says Mark Peplow